"Alkermes is honored to present at these notable scientific meetings, sharing our research and insights with thought leaders and healthcare providers from across the field of psychiatry," said Craig ...

* ALKERMES PLC - ‍EFFICACY AND SAFETY OF TWO-MONTH ARISTADA COMPARED TO MARKET LEADER INVEGA SUSTENNA WILL ALSO BE EVALUATED IN TRIAL Source text for Eikon: Further company coverage: ...

(Reuters) - The U.S. Food and Drug Administration on Monday approved Alkermes Plc's longer-acting injectable version of blockbuster schizophrenia pill Abilify, making the treatment available in two ...